CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 35.68×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
900.73MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
81.56%vs all stocks
Market Capitalization
900.73MUSDvs all stocks (USD)
Enterprise Value
538.57MUSDvs all stocks (USD)
Forward P/E
-7.13xvs Biotechnology peers
Price to Book (MRQ)
2.38xvs Biotechnology peers
Enterprise to EBITDA
-12.03xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-8.05%vs Biotechnology peers
Return on Equity (TTM)
-19.56%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-44.76MUSDvs all stocks (USD)
Net Income (TTM)
-38.95MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-50.37MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.20MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-30.40MUSDvs all stocks (USD)
Pre-tax Income
-25.20MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.00KUSDFY2025 · Dec 31, 2025Net Income
-25.20MUSDFY2025 · Dec 31, 2025EBIT
-30.40MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-31.36MUSDFY2025 · Dec 31, 2025Research & Development
16.74MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
13.66MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.92MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-25.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-20.95MUSDFY2025 · Dec 31, 2025Free Cash Flow
-21.00MUSDDerived from operating cash flow minus capital expenditure. This filing charges 321K of depreciation against 52K of capital expenditure, and its own free-cash-flow line reads -35.26M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
250.94MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.00KUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-25.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
321.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.19MUSDFY2025 · Dec 31, 2025Other Non-cash Items
147.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-268.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-134.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-52.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-44.84MUSDFY2025 · Dec 31, 2025Sale of Investments
5.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-39.89MUSDFY2025 · Dec 31, 2025Other Financing Charges
-25.43MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
302.31MUSDFY2025 · Dec 31, 2025Shares Outstanding
28.67MSharesUpdated Jul 19, 2026Float Shares
18.10MSharesUpdated Jul 19, 2026Shares Short
4.55MSharesUpdated Jul 19, 2026Short Ratio
14.19daysvs all stocks
Short % of Shares Outstanding
19.09%vs all stocks
% Held by Insiders
0.27%vs all stocks
% Held by Institutions
107.15%vs all stocks
Total Cash (MRQ)
365.64MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.75USDUpdated Jul 19, 2026Total Debt (MRQ)
3.47MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0092xvs Biotechnology peers
Current Ratio (MRQ)
35.67xvs Biotechnology peers
Book Value per Share (MRQ)
13.21USDUpdated Jul 19, 2026Total Assets
312.93MUSDvs all stocks (USD)
Total Current Assets
308.43MUSDFY2025 · Dec 31, 2025Total Liabilities
11.62MUSDFY2025 · Dec 31, 2025Total Non-current Assets
4.50MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.18MUSDFY2025 · Dec 31, 2025Total Current Liabilities
7.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
250.17MUSDFY2025 · Dec 31, 2025Other Short-term Investments
45.04MUSDFY2025 · Dec 31, 2025Accounts Payable
2.13MUSDFY2025 · Dec 31, 2025Short-term Debt
730.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.84MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-129.53MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
301.31MUSDvs all stocks (USD)
52-Week Low
13.36USDUpdated Jul 19, 202652-Week High
35.34USDUpdated Jul 19, 202652-Week Change
81.56%vs all stocks
50-Day MA
30.32USDUpdated Jul 19, 2026200-Day MA
23.77USDUpdated Jul 19, 2026Avg 10-Day Volume
216.62KSharesUpdated Jul 19, 2026Avg 30-Day Volume
301.89KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.39USDUpdated Jul 19, 2026Other Income / Expense
1.28MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 35.68×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 35.67Industry median: 5.64Industry P95: 23.02Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Wuhan Keqian Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Promotora y Operadora de Infraestructura, S.A.B. de C.V.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Pulse Biosciences Inc.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Shanghai Opm Biosciences Co., Ltd.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity